Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2026)

Amylyx Pharmaceuticals' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 95.1% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $194.6 million, a 195.37% increase from a year earlier, with the FY2025 full-year figure at $257.0 million, up 73758.91% from the prior year.
• Cash from Financing Activities climbed to $3.2 million in Q1 2026 per AMLX's latest filing, from -$208000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $232.2 million in Q4 2022 and bottomed at -$828000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $559500.0 (2023), against an average of $43.5 million.
• Biggest YoY gain for Cash from Financing Activities was 239407.5% in 2025; the steepest drop was 289.09% in 2025.
• Year by year, Cash from Financing Activities stood at $232.2 million in 2022, then sank by 99.9% to $230000.0 in 2023, then tumbled by 52.17% to $110000.0 in 2024, then tumbled by 289.09% to -$208000.0 in 2025, then soared by 1646.63% to $3.2 million in 2026.
• Per Business Quant, the three latest AMLX Cash from Financing Activities figures stand at $3.2 million (Q1 2026), -$208000.0 (Q4 2025), and $191.6 million (Q3 2025).